Your browser doesn't support javascript.
loading
Promoter methylation of MEG3 gene in hepatocellular carcinoma and its clinical significance / 肿瘤研究与临床
Cancer Research and Clinic ; (6): 85-88, 2018.
Article in Chinese | WPRIM | ID: wpr-712770
ABSTRACT
Objective To investigate promoter methylation state of MEG3 gene in hepatocellular carcinoma and its clinical significance. Methods Methylation-specific polymerase chain reaction (MSP) was performed to detect methylation of MEG3 promoter in 58 cases of hepatocellular carcinoma tissues and 20 cases of normal control from December 2014 to December 2016 in Shanxi Provincial Cancer Hospital, and to analyze the relationship between methylation and the clinicopathological features of the patients. Results The methylation incidence rate of MEG3 promoter in hepatocellular carcinoma tissues (55.2 %, 32/58) was higher than that in normal liver tissue (25.0 %, 5/20), and there was a significant statistical difference (χ2=6.72,P =0.02).There was no significant difference in the incidence of MEG3 methylation of the patients with different age, gender, α-fetoprotein levels, tumor number and differentiation (all P> 0.05). There was a significant difference in the incidence of MEG3 methylation of the patients with different tumors diameter, liver cirrhosis, hepatitis B surface antigen (HBsAg), TNM staging and distant metastasis (all P< 0.05). Conclusion Aberrant promoter methylation in MEG3 genes may be associated with the occurrence of hepatocellular carcinoma,tumor diameter,liver cirrhosis,HBsAg,TNM staging and distant metastasis.

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Cancer Research and Clinic Year: 2018 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Language: Chinese Journal: Cancer Research and Clinic Year: 2018 Type: Article